Engineered Mycobacterium smegmatis Boosts Antitumor Immunity
Author Information
Author(s): Hang Zhou, Junmeng Zhu, Mei Yi, Aoxing Chen, Rui Liu, Xiaonan Wang, Xiangyu Wu, Xiaotong Chen, Baorui Liu
Primary Institution: The Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Hypothesis
Can engineered Mycobacterium smegmatis enhance antitumor immunity and inhibit tumor growth?
Conclusion
The engineered Mycobacterium smegmatis significantly enhances antitumor immunity and inhibits tumor growth in mouse models.
Supporting Evidence
- Intratumoral injection of rM-FC significantly suppressed tumor growth in mouse models.
- rM-FC increased the number of mature dendritic cells in tumor-draining lymph nodes.
- Combination therapy with anti-PDL1 enhanced the antitumor effect and generated immune memory.
- rM-FC treatment resulted in a significant increase in CD8+ T cell activation.
- Engineered M. smegmatis localized primarily in tumors and tumor-draining lymph nodes.
Takeaway
Scientists created a special bacteria that helps the body's immune system fight cancer better, making tumors shrink.
Methodology
The study involved intratumoral injections of engineered Mycobacterium smegmatis in mouse models to assess immune response and tumor growth.
Potential Biases
Potential bias in the selection of tumor models and treatment regimens.
Limitations
The study did not provide enough data on immune changes in distant untreated tumors and some tumors relapsed later.
Participant Demographics
Male BALB/c and C57BL/6 mice aged 5 to 6 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website